Retatrutide is a peptide-based therapy that functions as a triple hormone receptor agonist, activating three important metabolic receptors at the same time:

• GLP-1 (glucagon-like peptide-1) receptor
• GIP (glucose-dependent insulinotropic polypeptide) receptor
• Glucagon receptor

By targeting all three pathways, Retatrutide is intended to influence appetite, energy balance, and glucose metabolism more effectively than medications that act on only one or two receptors.

How It Works

Retatrutide delivers three complementary metabolic actions in a single compound:

  1. Appetite Suppression & Satiety

• Stimulates GLP-1 pathways to reduce hunger signals and slow digestion, helping promote earlier satiety and lower food intake.

  2. Improved Metabolic Control

• Activates GIP pathways to support insulin release after meals and assist in maintaining balanced glucose levels.

3. Increased Energy Use & Fat Breakdown

• Engages glucagon receptors to boost energy use and promote fat oxidation.

Together, these effects contribute to stronger appetite suppression, improved glucose handling, and broader metabolic benefits compared to single- or dual-agonist treatments.

Retatrutide Uses

Current Uses Include:

1. Obesity and overweight management, with significant weight reduction observed in clinical studies
2. Type 2 diabetes, to support blood sugar control and insulin response
3. Metabolic dysfunction-associated steatotic liver disease (MASH) and cardiovascular risk factors, currently under investigation
4. Additional research is exploring applications for knee osteoarthritis, sleep apnea, and related metabolic conditions